<DOC>
	<DOCNO>NCT02019693</DOCNO>
	<brief_summary>Background : - Papillary RCC second common histologic subtype kidney cancer , account approximately 10-15 % case - Type 1 papillary RCC occur sporadic hereditary form , histologically identical . Non familial type 1 papillary RCC present solitary renal tumor bilateral , multifocal disease - There standard agent proven efficacy patient advance papillary RCC . - Patients disease localized kidney manage surgically patient advanced/unresectable disease usually manage community VEGF pathway antagonist mTOR inhibitor . - Activating mutation MET identify germline affect HPRC patient , predilection development bilateral , multifocal type 1 papillary RCC . Somatic MET mutation find subset patient non-inherited , sporadic papillary renal carcinoma - The investigational agent INC280 selective MET inhibitor lack activity VEGF pathway - This proof-of-concept study use INC280 patient papillary RCC test idea effectively block HGF/MET pathway lead clinical activity patient papillary renal cell cancer Objectives : Primary Objective : -To determine overall response rate ( RECIST 1.1 ) patient papillary renal cell carcinoma treat single agent INC280 Eligibility : - Diagnosis hereditary papillary renal carcinoma ( HPRC ) sporadic papillary renal cell carcinoma ( RCC ) - Patients bilateral multifocal disease tumor localize kidney metastatic disease - Patients sporadic papillary RCC ( without multifocal disease ) advance disease consider unresectable - ECOG 0-2 - Measurable disease - Adequate organ function - No active brain metastasis - Prior therapy - No 3 prior line systemic therapy - Prior therapy MET inhibitor allow long patient progressive disease receive agent Design : - This phase 2 single center non-randomized trial . - The study conduct use Simon 2 stage minimax design . Initially 13 evaluable subject recruit . If response therapy , study terminate . If least 1 response additional 7 evaluable subject accrue . - The two-stage minimax design base assume ineffective response rate 5 % target effective response rate 25 % . We also assume probability accept ineffective treatment probability reject effective treatment 10 % . - Subjects dose orally start dose 600 mg twice daily . - The overall response rate ( complete response + partial response ) determine .</brief_summary>
	<brief_title>A Phase 2 Study MET Kinase Inhibitor INC280 Papillary Renal Cell Cancer</brief_title>
	<detailed_description>Background : - Papillary RCC second common histologic subtype kidney cancer , account approximately 10-15 % case - Type 1 papillary RCC occur sporadic hereditary form , histologically identical . Non familial type 1 papillary RCC present solitary renal tumor bilateral , multifocal disease - There standard agent proven efficacy patient advance papillary RCC . - Patients disease localized kidney manage surgically patient advanced/unresectable disease usually manage community VEGF pathway antagonist mTOR inhibitor . - Activating mutation MET identify germline affect HPRC patient , predilection development bilateral , multifocal type 1 papillary RCC . Somatic MET mutation find subset patient non-inherited , sporadic papillary renal carcinoma - The investigational agent INC280 selective MET inhibitor lack activity VEGF pathway - This proof-of-concept study use INC280 patient papillary RCC test idea effectively block HGF/MET pathway lead clinical activity patient papillary renal cell cancer Objectives : Primary Objective : -To determine overall response rate ( RECIST 1.1 ) patient papillary renal cell carcinoma treat single agent INC280 Eligibility : - Diagnosis hereditary papillary renal carcinoma ( HPRC ) sporadic papillary renal cell carcinoma ( RCC ) - Patients bilateral multifocal disease tumor localize kidney metastatic disease - Patients sporadic papillary RCC ( without multifocal disease ) advance disease consider unresectable - ECOG 0-2 - Measurable disease - Adequate organ function - No active brain metastasis - Prior therapy - No 3 prior line systemic therapy - Prior therapy MET inhibitor allow long patient progressive disease receive agent Design : - This phase 2 single center non-randomized trial . - The study conduct use Simon 2 stage minimax design . Initially 13 evaluable subject recruit . If response therapy , study terminate . If least 1 response additional 7 evaluable subject accrue . - The two-stage minimax design base assume ineffective response rate 5 % target effective response rate 25 % . We also assume probability accept ineffective treatment probability reject effective treatment 10 % . - Subjects dose orally start dose 400 mg twice daily . - The overall response rate ( complete response + partial response ) determine .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>INCLUSION CRITERIA 2.1.1.1 Patients must histologically cytologically confirm papillary RCC . 1 . Patients bilateral multifocal disease tumor localize kidney metastatic disease 2 . Patients sporadic papillary RCC ( without multifocal disease ) advance disease consider unresectable 2.1.1.2 Patients must measurable disease , define least one lesion accurately measure least one dimension ( long diameter record nonnodal lesion short axis nodal lesion ) . Nodal lesion must ( Bullet ) 15mm CT scan MRI . Non nodal lesion must &gt; 10 mm CT scan MRI . 2.1.1.3 Patients must normal organ marrow function define : Hemoglobin &gt; 9 g/dL ( SI Units : 90 g/L ) Platelet count great equal 75 x 10 ( 9 ) /L Absolute neutrophil count ( ANC ) great equal 1.5 x 10 ( 9 ) /L without growth factor support Total bilirubin less equal 2 x upper limit normal ( ULN ) AST/SGOT and/or ALT/SGPT le equal 2.5 x upper limit normal ( ULN ) Serum creatinine less equal 1.5 x ULN Asymptomatic serum amylase less equal 2 x ULN ; patient &gt; ULN le equal 2 x ULN serum amylase study start must confirm sign and/or symptom suggestion pancreatitis pancreatic injury ( e.g . elevated Pamylase , abnormal imaging finding pancreas , etc . ) Serum lipase less equal ULN Fasting serum triglyceride level le equal 500 mg/dL 2.1.1.4 Patients may 3 prior line systemic therapy . Prior therapy MET inhibitor allow long patient progressive disease receive agent 2.1.1.5 Patient must able swallow retain oral medication 2.1.1.6 Age great equal to18 year . 2.1.1.7 ECOG performance status 0 2 . 2.1.1.8 Patients must provide write informed consent prior study procedure . 2.1.1.9 Patients must willing able comply schedule visit , treatment plan laboratory test EXCLUSION CRITERIA 2.1.2.1 Patients receive investigational agent treatment kidney cancer . 2.1.2.2 History allergic reaction attribute compound similar chemical biologic composition INC280 . Excipients current formulation include microcrystalline cellulose , mannitol , sodium starch glycolate , magnesium stearate colloidal silicon dioxide 2.1.2.3 Uncontrolled intercurrent illness include , limited , ongoing active infection require intravenous antibiotic , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement potentially affect interpretation study data . 2.1.2.4 Subjects significant uncontrolled cardiovascular disease ( e.g. , uncontrolled hypertension , peripheral vascular disease , congestive heart failure , cardiac arrhythmia , acute coronary syndrome ) within 6 month prior start study treatment heart attack within 12 month prior start study treatment 2.1.2.5 Patients receive medication know strong inducer inhibitor CYP3A4 , sensitive substrate CYP3A4 , CYP1A2 , CYP2C9 , CYP2C9 , CYP2C19 Pgp narrow therapeutic index . 2.1.2.6 Symptomatic CNS metastasis neurologically unstable require &gt; 5 mg/day dexamethasone ( equivalent ) control CNS disease . Note : Patients control CNS metastasis allow . Radiotherapy surgery CNS metastases must complete &gt; 2 week prior study entry . Patients must neurologically stable , new neurologic deficit clinical examination , new finding CNS imaging . Steroid use management CNS metastases must stable dose two week precede study entry . 2.1.2.7 Patients great equal Grade 2 neuropathy . 2.1.2.8 Treatment proton pump inhibitor within 3 day prior study entry . If continue use GI prophylaxis require , patient switch appropriate H2 antagonist appropriate counsel caution . 2.1.2.9 Currently receive prohibit medication include vitamin herbal Supplements . 2.1.2.10 Major surgery within 4 week prior initiate treatment , exclude placement vascular access . 2.1.2.11 The subject recover baseline , CTCAE less equal Grade 1 toxicity due prior therapy RCC level permit section eligibility criterion except alopecia nonclinically significant AEs . 2.1.2.12 Any condition would , Investigator judgment , contraindicate participation clinical study due safety concern compliance clinical study procedure , e.g. , infection/inflammation , intestinal obstruction , unable swallow medication , social/ psychological issue , etc . 2.1.2.13 Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test ( &gt; 30 mIU/mL ) . Laboratory value &gt; 5 mIU/mL , &lt; 30 mIU/mL repeat 48 hour . 2.1.2.14 Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception dose 3 month day stop study drug . Highly effective contraception method include : Total abstinence Male female sterilization Combination two follow ( a+b a+c b+c ) : 1 . Use oral , injected implant hormonal method contraception 2 . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) 3 . Barrier method contraception : condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/vaginal suppository Women consider postmenopausal child bear potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g . age appropriate , history vasomotor symptom ) surgical bilateral oophorectomy ( without hysterectomy ) tubal ligation least six week ago . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider child bear potential . 2.1.2.15 Sexually active male must use condom intercourse take drug 3 month stop study drug father child period . A condom require use also vasectomize men order prevent delivery drug via seminal fluid . 2.1.2.16 HIVpositive patient combination antiretroviral therapy ineligible potential pharmacokinetic interaction INC280 . 2.1.2.17 Prior invasive malignancy histology currently require treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>September 27, 2016</verification_date>
	<keyword>MET Inhibitor</keyword>
	<keyword>Sporadic</keyword>
	<keyword>Hereditary</keyword>
	<keyword>Multifocal</keyword>
	<keyword>HGF/MET Pathway</keyword>
</DOC>